Good Neighbor Pharmacy expands immunization programs for pharmacists
VALLEY FORGE, Pa. — Good Neighbor Pharmacy recently signed an agreement with the University of Southern California, providing a unique, international travel health program for community pharmacists, the company announced Friday.
As part of a larger immunization certification program, Good Neighbor Pharmacy members, a network of more than 3,700 locally owned and operated community pharmacies, are eligible to enroll in a training program that offers comprehensive pretravel health services in the convenient community pharmacy setting.
Pharmacists who have received certification to administer specific immunizations and vaccines in their state are eligible for this travel health program. International travel health experts at the University of Southern California School of Pharmacy will provide additional training and clinical support to participating pharmacists. Pharmacists will gather information from their patients and work with the USC Travel Medicine Assistance Program to give patient and destination-specific recommendations for vaccines, prescription and over-the-counter medications, travel supplies and counseling topics. Local pharmacists see the patient, equipped with expert information from USC Travel MAP.
“Working with USC Travel MAP gives another opportunity for our Good Neighbor Pharmacies to be a resource for their patients, which is consistent with Good Neighbor Pharmacy’s goal of becoming a healthcare destination,” Good Neighbor Pharmacy president Mike Cantrell said. “Pharmacists certified to provide immunizations, and acquire this additional training, will be providing one more important professional, convenient service for their patients.”
Good Neighbor Pharmacy members learned of the USC Travel MAP at the National Healthcare Conference and Exposition held in Las Vegas this past week.
NACDS outlines role of pharmacy in patient care to Senate committee
ALEXANDRIA, Va. — The National Association of Chain Drug Stores announced Thursday that it has submitted comments to the U.S. Senate Special Committee on Aging outlining the value of the pharmacist-patient interaction in helping improve health and reduce costs in the Medicare program, and urged the committee to support the Medication Therapy Management Empowerment Act of 2011, which seeks to increase access to pharmacy services for Medicare beneficiaries.
NACDS submitted its comments in conjunction with the committee’s hearing, titled "A Prescription for Savings: Reducing Drug Costs to Medicare."
"Pharmacists play a key role in helping patients take their medications as prescribed and offer a variety of pharmacist-delivered services, such as medication therapy management, to improve quality and outcomes while reducing overall costs at the same time," NACDS stated in its comments. "Community pharmacists are uniquely qualified through their comprehensive education and training to significantly reduce the problem of poor medication adherence."
"As medication-use experts, pharmacists assist patients in achieving positive outcomes from their medication therapy. Pharmacists help patients every day by counseling on proper use of medications, checking for possible side effects, drug interactions or allergies, and helping to coordinate insurance benefits," NACDS added.
In the letter, NACDS also pressed the committee to support the Medication Therapy Management Empowerment Act of 2011 (S. 274), which seeks to increase access to pharmacy services for Medicare beneficiaries. The comments also outlined how increasing the use of generic medications can promote cost savings in the Medicare program.
"Increasing the rate at which generic pharmaceuticals are substituted for their brand-name equivalents or other brand-name drugs within the same drug classes is a cost-effective way of achieving Medicare Part D savings," NACDS stated in its comments. "By providing medication therapy management, increasing medication adherence, and promoting and increasing the use of generic medications, pharmacies and pharmacists continue to increase the healthcare quality and outcomes for Part D beneficiaries, while at the same time reducing overall program costs," the comments concluded.
FDA panel recommends approval of Remicade for UC in children
HORSHAM, Pa. — A panel of experts at the Food and Drug Administration has recommended that the agency approve a drug made by Johnson & Johnson as a treatment for ulcerative colitis in children.
J&J subsidiary Janssen Biotech, which formerly went under the name Centocor Ortho Biotech, said the FDA’s Gastrointestinal Drugs Advisory Committee recommended approval of Remicade (infliximab) for moderately to severely active ulcerative colitis in children who have not responded to conventional therapies. The FDA granted orphan drug designation to Remicade as a treatment for UC in children in 2003; the agency gives orphan drug designation to drugs for diseases that affect fewer than 200,000 people.
“We are pleased with the advisory committee’s support for the approval of Remicade as a treatment for pediatric ulcerative colitis,” said Jerome Boscia, VP and head of immunology development for the Centocor Research & Development division of J&J Pharmaceutical Research & Development. “We hope the FDA will consider this recommendation and approve Remicade for this orphan disease.”